LakeShore Biopharma (LSB) Competitors $0.79 +0.02 (+3.15%) Closing price 08/14/2025 03:59 PM EasternExtended Trading$0.78 -0.01 (-0.63%) As of 08/14/2025 05:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSB vs. RPTX, OTLK, MNOV, STRO, VNRX, PYXS, GNTA, INMB, APLT, and IRDShould you be buying LakeShore Biopharma stock or one of its competitors? The main competitors of LakeShore Biopharma include Repare Therapeutics (RPTX), Oncobiologics (OTLK), MediciNova (MNOV), Sutro Biopharma (STRO), VolitionRx (VNRX), Pyxis Oncology (PYXS), Genenta Science (GNTA), INmune Bio (INMB), Applied Therapeutics (APLT), and Opus Genetics (IRD). These companies are all part of the "pharmaceutical products" industry. LakeShore Biopharma vs. Its Competitors Repare Therapeutics Oncobiologics MediciNova Sutro Biopharma VolitionRx Pyxis Oncology Genenta Science INmune Bio Applied Therapeutics Opus Genetics LakeShore Biopharma (NASDAQ:LSB) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Which has more volatility and risk, LSB or RPTX? LakeShore Biopharma has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Does the media favor LSB or RPTX? In the previous week, Repare Therapeutics had 5 more articles in the media than LakeShore Biopharma. MarketBeat recorded 8 mentions for Repare Therapeutics and 3 mentions for LakeShore Biopharma. LakeShore Biopharma's average media sentiment score of 1.28 beat Repare Therapeutics' score of 0.56 indicating that LakeShore Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LakeShore Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repare Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in LSB or RPTX? 52.6% of LakeShore Biopharma shares are owned by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are owned by institutional investors. 11.5% of Repare Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is LSB or RPTX more profitable? LakeShore Biopharma's return on equity of 0.00% beat Repare Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LakeShore BiopharmaN/A N/A N/A Repare Therapeutics N/A -78.25%-66.85% Do analysts recommend LSB or RPTX? Repare Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 188.46%. Given Repare Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Repare Therapeutics is more favorable than LakeShore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LakeShore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better valuation & earnings, LSB or RPTX? LakeShore Biopharma has higher revenue and earnings than Repare Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLakeShore Biopharma$85.67M0.19-$13.93MN/AN/ARepare Therapeutics$53.48M1.25-$84.69M-$2.58-0.60 SummaryRepare Therapeutics beats LakeShore Biopharma on 8 of the 13 factors compared between the two stocks. Get LakeShore Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LSB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSB vs. The Competition Export to ExcelMetricLakeShore BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.90M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.4930.2825.74Price / Sales0.19356.37460.47115.79Price / CashN/A43.0338.2159.48Price / Book0.248.608.856.15Net Income-$13.93M-$54.65M$3.25B$265.06M7 Day Performance12.86%5.86%3.72%2.60%1 Month Performance-25.47%8.86%5.86%2.83%1 Year Performance-82.48%13.33%30.34%25.58% LakeShore Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSBLakeShore Biopharma1.4836 of 5 stars$0.79+3.1%N/A-82.0%$15.90M$85.67M0.00773Positive NewsUpcoming EarningsShort Interest ↓Gap DownRPTXRepare Therapeutics2.8038 of 5 stars$1.56+1.3%$4.50+188.5%-44.7%$66.16M$53.48M-0.60180Earnings ReportOTLKOncobiologics1.7889 of 5 stars$2.09+6.6%$9.60+359.3%-66.9%$65.79MN/A-2.3020News CoverageEarnings ReportGap DownHigh Trading VolumeMNOVMediciNova2.4559 of 5 stars$1.30-2.9%$7.00+438.5%+15.0%$65.69M$1M-5.6510STROSutro Biopharma4.2263 of 5 stars$0.78+1.4%$5.97+662.0%-78.3%$65.50M$62.04M-0.31240Analyst ForecastVNRXVolitionRx2.6823 of 5 stars$0.62flat$3.50+464.5%+16.5%$64.47M$1.31M-1.7280News CoverageGap UpPYXSPyxis Oncology2.3726 of 5 stars$1.04flat$8.67+733.3%-66.4%$64.43M$16.15M-0.6560News CoverageEarnings ReportGNTAGenenta Science2.7987 of 5 stars$3.29-5.7%$25.00+659.9%-23.8%$63.83MN/A0.007Positive NewsGap UpINMBINmune Bio2.3747 of 5 stars$2.42+0.8%$18.40+660.3%-63.6%$63.81M$10K-0.9810APLTApplied Therapeutics4.4085 of 5 stars$0.44-2.0%$6.10+1,286.4%-92.0%$63.58M$460K-1.0230News CoveragePositive NewsEarnings ReportShort Interest ↓Gap DownIRDOpus Genetics1.863 of 5 stars$1.11+4.7%$7.33+560.7%N/A$63.24M$13.65M-0.5314News CoverageEarnings ReportGap Down Related Companies and Tools Related Companies Repare Therapeutics Competitors Oncobiologics Competitors MediciNova Competitors Sutro Biopharma Competitors VolitionRx Competitors Pyxis Oncology Competitors Genenta Science Competitors INmune Bio Competitors Applied Therapeutics Competitors Opus Genetics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSB) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LakeShore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share LakeShore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access